Advanced search
Publication Cover
Current Medical Research and Opinion Volume 30, 2014 - Issue 6
Submit an article Journal homepage
581
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Monitoring the efficacy of once-weekly teriparatide. Are bone turnover markers useful in predicting fracture risk?

Panagiotis AnagnostisDivision of Endocrinology, Police Medical Centre of Thessaloniki Sarantaporou 10, Thessaloniki, 54 640Greece;Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of ThessalonikiGreeceCorrespondence[email protected]
,
Spyridon N. KarrasUnit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of ThessalonikiGreece
&
Dimitrios G. GoulisUnit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of ThessalonikiGreece
Pages 1177-1178 | Published online: 06 Mar 2014

References

  • Tanaka S, Kuroda T, Sugimoto T, et al. Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide. Curr Med Res Opin 2014;30:931-6
  • Nakamura T, Sugimoto T, Nakano T, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 2012;97:3097-106
  • Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 2006;7:113-21
  • Ito M, Oishi R, Fukunaga M, et al. The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT. Osteoporos Int 2014;25:1163-72
  • Watts NB, Geusens P, Barton IP, et al. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 2005;20:2097-104
  • Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004;7:255-61
  • Nakamura T, Tsujimoto M, Hamaya E, et al. Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide: a meta-analysis. J Bone Miner Metab 2012;30:321-5
  • Watts NB, Adler RA, Bilezikian JP, et al.; Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:1802-22
  • Diez-Perez A, Adachi JD, Agnusdei D, et al.; IOF CSA Inadequate Responders Working Group. treatment failure in osteoporosis. Osteoporos Int 2012;23:2769-74

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.